XML 47 R29.htm IDEA: XBRL DOCUMENT
v3.22.1

Segments of Business and Geographic Areas (Tables) | 3 Months Ended
--- | ---
Apr. 03, 2022
Segment Reporting [Abstract] |
Sales By Segment Of Business | SALES BY SEGMENT OF BUSINESS
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | Percent Change |  |  |  |  |  |
CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  |
OTC(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $ | 670 |  |  | 599 |  |  | 11.8 | % |  |  |  |  |  |
International |  | 791 |  |  | 673 |  |  | 17.5 |  |  |  |  |  |  |
Worldwide |  | 1,461 |  |  | 1,273 |  |  | 14.8 |  |  |  |  |  |  |
Skin Health/Beauty |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 544 |  |  | 634 |  |  | (14.2) |  |  |  |  |  |  |
International |  | 468 |  |  | 529 |  |  | (11.6) |  |  |  |  |  |  |
Worldwide |  | 1,012 |  |  | 1,163 |  |  | (13.0) |  |  |  |  |  |  |
Oral Care |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 143 |  |  | 163 |  |  | (12.6) |  |  |  |  |  |  |
International |  | 223 |  |  | 254 |  |  | (12.0) |  |  |  |  |  |  |
Worldwide |  | 366 |  |  | 417 |  |  | (12.2) |  |  |  |  |  |  |
Baby Care |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 85 |  |  | 96 |  |  | (11.5) |  |  |  |  |  |  |
International |  | 270 |  |  | 293 |  |  | (7.7) |  |  |  |  |  |  |
Worldwide |  | 355 |  |  | 389 |  |  | (8.6) |  |  |  |  |  |  |
Women's Health |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 3 |  |  | 3 |  |  | 7.2 |  |  |  |  |  |  |
International |  | 224 |  |  | 219 |  |  | 2.5 |  |  |  |  |  |  |
Worldwide |  | 228 |  |  | 222 |  |  | 2.6 |  |  |  |  |  |  |
Wound Care/Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 112 |  |  | 115 |  |  | (3.3) |  |  |  |  |  |  |
International |  | 52 |  |  | 61 |  |  | (15.3) |  |  |  |  |  |  |
Worldwide |  | 164 |  |  | 177 |  |  | (7.4) |  |  |  |  |  |  |
TOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,557 |  |  | 1,611 |  |  | (3.4) |  |  |  |  |  |  |
International |  | 2,029 |  |  | 2,030 |  |  | 0.0 |  |  |  |  |  |
Worldwide |  | 3,586 |  |  | 3,641 |  |  | (1.5) |  |  |  |  |  |  |
PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  |
Immunology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,501 |  |  | 2,413 |  |  | 3.7 |  |  |  |  |  |  |
International |  | 1,617 |  |  | 1,501 |  |  | 7.7 |  |  |  |  |  |  |
Worldwide |  | 4,119 |  |  | 3,914 |  |  | 5.2 |  |  |  |  |  |  |
REMICADE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 358 |  |  | 489 |  |  | (26.8) |  |  |  |  |  |  |
U.S. Exports |  | 80 |  |  | 57 |  |  | 40.5 |  |  |  |  |  |  |
International |  | 225 |  |  | 232 |  |  | (2.6) |  |  |  |  |  |  |
Worldwide |  | 663 |  |  | 777 |  |  | (14.7) |  |  |  |  |  |  |
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 287 |  |  | 255 |  |  | 12.5 |  |  |  |  |  |  |
International |  | 283 |  |  | 307 |  |  | (7.6) |  |  |  |  |  |  |
Worldwide |  | 571 |  |  | 562 |  |  | 1.5 |  |  |  |  |  |  |
STELARA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,379 |  |  | 1,331 |  |  | 3.6 |  |  |  |  |  |  |
International |  | 909 |  |  | 817 |  |  | 11.2 |  |  |  |  |  |  |
Worldwide |  | 2,288 |  |  | 2,148 |  |  | 6.5 |  |  |  |  |  |  |
TREMFYA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 391 |  |  | 274 |  |  | 42.7 |  |  |  |  |  |  |
International |  | 199 |  |  | 143 |  |  | 38.8 |  |  |  |  |  |  |
Worldwide |  | 590 |  |  | 418 |  |  | 41.3 |  |  |  |  |  |  |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 6 |  |  | 7 |  |  | (3.2) |  |  |  |  |  |  |
International |  | 0 |  |  | 2 |  |  | * |  |  |  |  |  |
Worldwide |  | 6 |  |  | 8 |  |  | (22.0) |  |  |  |  |  |  |
Infectious Diseases |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 461 |  |  | 512 |  |  | (10.0) |  |  |  |  |  |  |
International |  | 836 |  |  | 485 |  |  | 72.3 |  |  |  |  |  |  |
Worldwide |  | 1,297 |  |  | 998 |  |  | 30.0 |  |  |  |  |  |  |
COVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 75 |  |  | 100 |  |  | (24.9) |  |  |  |  |  |  |
International |  | 382 |  |  | 0 |  | * |  |  |  |  |  |
Worldwide |  | 457 |  |  | 100 |  |  | * |  |  |  |  |  |
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 9 |  |  | 10 |  |  | (12.6) |  |  |  |  |  |  |
International |  | 239 |  |  | 233 |  |  | 2.5 |  |  |  |  |  |  |
Worldwide |  | 248 |  |  | 243 |  |  | 1.8 |  |  |  |  |  |  |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 369 |  |  | 380 |  |  | (3.1) |  |  |  |  |  |  |
International |  | 132 |  |  | 166 |  |  | (20.3) |  |  |  |  |  |  |
Worldwide |  | 501 |  |  | 546 |  |  | (8.3) |  |  |  |  |  |  |
OTHER INFECTIOUS DISEASES(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 8 |  |  | 21 |  |  | (62.5) |  |  |  |  |  |  |
International |  | 83 |  |  | 87 |  |  | (3.8) |  |  |  |  |  |  |
Worldwide |  | 91 |  |  | 108 |  |  | (15.3) |  |  |  |  |  |  |
Neuroscience |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 843 |  |  | 771 |  |  | 9.3 |  |  |  |  |  |  |
International |  | 898 |  |  | 943 |  |  | (4.8) |  |  |  |  |  |  |
Worldwide |  | 1,741 |  |  | 1,715 |  |  | 1.5 |  |  |  |  |  |  |
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 35 |  |  | 47 |  |  | (26.5) |  |  |  |  |  |  |
International |  | 122 |  |  | 123 |  |  | (1.3) |  |  |  |  |  |  |
Worldwide |  | 157 |  |  | 171 |  |  | (8.3) |  |  |  |  |  |  |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 661 |  |  | 589 |  |  | 12.2 |  |  |  |  |  |  |
International |  | 387 |  |  | 376 |  |  | 3.0 |  |  |  |  |  |  |
Worldwide |  | 1,048 |  |  | 965 |  |  | 8.6 |  |  |  |  |  |  |
RISPERDAL CONSTA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 63 |  |  | 67 |  |  | (6.4) |  |  |  |  |  |  |
International |  | 66 |  |  | 89 |  |  | (26.1) |  |  |  |  |  |  |
Worldwide |  | 129 |  |  | 157 |  |  | (17.6) |  |  |  |  |  |  |
OTHER NEUROSCIENCE(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 84 |  |  | 67 |  |  | 25.5 |  |  |  |  |  |  |
International |  | 323 |  |  | 355 |  |  | (8.9) |  |  |  |  |  |  |
Worldwide |  | 408 |  |  | 422 |  |  | (3.5) |  |  |  |  |  |  |
Oncology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,582 |  |  | 1,377 |  |  | 14.9 |  |  |  |  |  |  |
International |  | 2,369 |  |  | 2,193 |  |  | 8.0 |  |  |  |  |  |  |
Worldwide |  | 3,950 |  |  | 3,570 |  |  | 10.6 |  |  |  |  |  |  |
DARZALEX |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 953 |  |  | 691 |  |  | 37.9 |  |  |  |  |  |  |
International |  | 903 |  |  | 674 |  |  | 34.0 |  |  |  |  |  |  |
Worldwide |  | 1,856 |  |  | 1,365 |  |  | 36.0 |  |  |  |  |  |  |
ERLEADA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 206 |  |  | 171 |  |  | 20.3 |  |  |  |  |  |  |
International |  | 194 |  |  | 90 |  |  | * |  |  |  |  |  |
Worldwide |  | 400 |  |  | 261 |  |  | 53.0 |  |  |  |  |  |  |
IMBRUVICA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 370 |  |  | 444 |  |  | (16.7) |  |  |  |  |  |  |
International |  | 668 |  |  | 680 |  |  | (1.8) |  |  |  |  |  |  |
Worldwide |  | 1,038 |  |  | 1,125 |  |  | (7.7) |  |  |  |  |  |  |
ZYTIGA / abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 19 |  |  | 50 |  |  | (62.1) |  |  |  |  |  |  |
International |  | 520 |  |  | 588 |  |  | (11.6) |  |  |  |  |  |  |
Worldwide |  | 539 |  |  | 638 |  |  | (15.6) |  |  |  |  |  |  |
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 34 |  |  | 21 |  |  | 63.1 |  |  |  |  |  |  |
International |  | 84 |  |  | 161 |  |  | (47.7) |  |  |  |  |  |  |
Worldwide |  | 118 |  |  | 182 |  |  | (35.1) |  |  |  |  |  |  |
Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 572 |  |  | 573 |  |  | (0.2) |  |  |  |  |  |  |
International |  | 279 |  |  | 288 |  |  | (2.9) |  |  |  |  |  |  |
Worldwide |  | 852 |  |  | 861 |  |  | (1.1) |  |  |  |  |  |  |
OPSUMIT |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 273 |  |  | 272 |  |  | 0.5 |  |  |  |  |  |  |
International |  | 170 |  |  | 179 |  |  | (4.8) |  |  |  |  |  |  |
Worldwide |  | 443 |  |  | 450 |  |  | (1.6) |  |  |  |  |  |  |
UPTRAVI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 269 |  |  | 259 |  |  | 3.9 |  |  |  |  |  |  |
International |  | 56 |  |  | 46 |  |  | 20.9 |  |  |  |  |  |  |
Worldwide |  | 325 |  |  | 305 |  |  | 6.5 |  |  |  |  |  |  |
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 30 |  |  | 42 |  |  | (29.0) |  |  |  |  |  |  |
International |  | 53 |  |  | 63 |  |  | (15.2) |  |  |  |  |  |  |
Worldwide |  | 83 |  |  | 105 |  |  | (20.8) |  |  |  |  |  |  |
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 672 |  |  | 799 |  |  | (15.8) |  |  |  |  |  |  |
International |  | 238 |  |  | 245 |  |  | (3.0) |  |  |  |  |  |  |
Worldwide |  | 910 |  |  | 1,044 |  |  | (12.8) |  |  |  |  |  |  |
XARELTO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 508 |  |  | 589 |  |  | (13.8) |  |  |  |  |  |  |
International |  | — |  |  | — |  |  | — |  |  |  |  |  |  |
Worldwide |  | 508 |  |  | 589 |  |  | (13.8) |  |  |  |  |  |  |
INVOKANA / INVOKAMET |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 60 |  |  | 87 |  |  | (30.7) |  |  |  |  |  |  |
International |  | 68 |  |  | 63 |  |  | 7.5 |  |  |  |  |  |  |
Worldwide |  | 128 |  |  | 150 |  |  | (14.6) |  |  |  |  |  |  |
OTHER(1,2) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 104 |  |  | 122 |  |  | (14.9) |  |  |  |  |  |  |
International |  | 170 |  |  | 182 |  |  | (6.6) |  |  |  |  |  |  |
Worldwide |  | 274 |  |  | 305 |  |  | (10.0) |  |  |  |  |  |  |
TOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 6,632 |  |  | 6,446 |  |  | 2.9 |  |  |  |  |  |  |
International |  | 6,237 |  |  | 5,655 |  |  | 10.3 |  |  |  |  |  |  |
Worldwide |  | 12,869 |  |  | 12,101 |  |  | 6.3 |  |  |  |  |  |  |
MEDTECH(3) |  |  |  |  |  |  |  |  |  |  |  |
Interventional Solutions |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 494 |  |  | 434 |  |  | 13.8 |  |  |  |  |  |  |
International |  | 597 |  |  | 514 |  |  | 16.2 |  |  |  |  |  |  |
Worldwide |  | 1,092 |  |  | 949 |  |  | 15.1 |  |  |  |  |  |  |
Orthopaedics |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,289 |  |  | 1,249 |  |  | 3.2 |  |  |  |  |  |  |
International |  | 899 |  |  | 864 |  |  | 4.1 |  |  |  |  |  |  |
Worldwide |  | 2,188 |  |  | 2,113 |  |  | 3.5 |  |  |  |  |  |  |
HIPS |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 225 |  |  | 209 |  |  | 7.3 |  |  |  |  |  |  |
International |  | 164 |  |  | 146 |  |  | 12.2 |  |  |  |  |  |  |
Worldwide |  | 389 |  |  | 356 |  |  | 9.3 |  |  |  |  |  |  |
KNEES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 201 |  |  | 185 |  |  | 8.6 |  |  |  |  |  |  |
International |  | 138 |  |  | 132 |  |  | 4.1 |  |  |  |  |  |  |
Worldwide |  | 339 |  |  | 317 |  |  | 6.7 |  |  |  |  |  |  |
TRAUMA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 475 |  |  | 450 |  |  | 5.5 |  |  |  |  |  |  |
International |  | 273 |  |  | 282 |  |  | (3.3) |  |  |  |  |  |  |
Worldwide |  | 748 |  |  | 733 |  |  | 2.1 |  |  |  |  |  |  |
SPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 387 |  |  | 404 |  |  | (4.1) |  |  |  |  |  |  |
International |  | 324 |  |  | 303 |  |  | 7.0 |  |  |  |  |  |  |
Worldwide |  | 712 |  |  | 707 |  |  | 0.6 |  |  |  |  |  |  |
Surgery |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 921 |  |  | 898 |  |  | 2.5 |  |  |  |  |  |  |
International |  | 1,513 |  |  | 1,474 |  |  | 2.7 |  |  |  |  |  |  |
Worldwide |  | 2,434 |  |  | 2,372 |  |  | 2.6 |  |  |  |  |  |  |
ADVANCED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 417 |  |  | 405 |  |  | 3.0 |  |  |  |  |  |  |
International |  | 729 |  |  | 713 |  |  | 2.2 |  |  |  |  |  |  |
Worldwide |  | 1,146 |  |  | 1,118 |  |  | 2.5 |  |  |  |  |  |  |
GENERAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 504 |  |  | 493 |  |  | 2.1 |  |  |  |  |  |  |
International |  | 784 |  |  | 761 |  |  | 3.1 |  |  |  |  |  |  |
Worldwide |  | 1,288 |  |  | 1,254 |  |  | 2.7 |  |  |  |  |  |  |
Vision |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 521 |  |  | 472 |  |  | 10.4 |  |  |  |  |  |  |
International |  | 736 |  |  | 673 |  |  | 9.4 |  |  |  |  |  |  |
Worldwide |  | 1,257 |  |  | 1,145 |  |  | 9.8 |  |  |  |  |  |  |
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 400 |  |  | 371 |  |  | 7.7 |  |  |  |  |  |  |
International |  | 511 |  |  | 486 |  |  | 5.1 |  |  |  |  |  |  |
Worldwide |  | 910 |  |  | 857 |  |  | 6.2 |  |  |  |  |  |  |
SURGICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 121 |  |  | 101 |  |  | 20.2 |  |  |  |  |  |  |
International |  | 226 |  |  | 187 |  |  | 20.5 |  |  |  |  |  |  |
Worldwide |  | 347 |  |  | 288 |  |  | 20.4 |  |  |  |  |  |  |
TOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 3,225 |  |  | 3,054 |  |  | 5.6 |  |  |  |  |  |  |
International |  | 3,746 |  |  | 3,525 |  |  | 6.3 |  |  |  |  |  |  |
Worldwide |  | 6,971 |  |  | 6,579 |  |  | 5.9 |  |  |  |  |  |  |
WORLDWIDE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 11,414 |  |  | 11,111 |  |  | 2.7 |  |  |  |  |  |  |
International |  | 12,012 |  |  | 11,210 |  |  | 7.2 |  |  |  |  |  |  |
Worldwide |  | $ | 23,426 |  |  | 22,321 |  |  | 5.0 | % |  |  |  |  |  |
*Percentage greater than 100% or not meaningful (1) In the fiscal first quarter of 2021, approximately $0.1 billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes (2) Inclusive of PROCRIT / EPREX which was previously disclosed separately (3) Previously referred to as Medical Devices
Operating Profit by Segment of Business | EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*
|  | Fiscal First Quarter Ended |  |  |
(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | Percent Change |  |  |  |  |  |  |  |  |  |  |
Consumer Health (1) |  | $ | 686 |  |  | 842 |  |  | (18.5)% |  |  |  |  |  |  |  |  |  |  |
Pharmaceutical(2) |  | 3,924 |  |  | 5,169 |  |  | (24.1) |  |  |  |  |  |  |  |  |  |  |
MedTech(3) |  | 1,477 |  |  | 1,629 |  |  | (9.3) |  |  |  |  |  |  |  |  |  |  |
Segment earnings before provision for taxes |  | 6,087 |  |  | 7,640 |  |  | (20.3) |  |  |  |  |  |  |  |  |  |  |
Less: Expense not allocated to segments (4) |  | 123 |  |  | 211 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Less: Consumer Health separation costs |  | 102 |  |  | — |  |  |  |  |  |  |  |  |  |  |  |  |  |
Worldwide income before tax |  | $ | 5,862 |  |  | 7,429 |  |  | (21.1)% |  |  |  |  |  |  |  |  |  |  |
*Fiscal first quarter 2021 earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes (1) Consumer Health includes: •Intangible amortization expense of $0.1 billion in both the fiscal first quarter of 2022 and 2021 (2) Pharmaceutical includes: •Divestiture gains of $0.6 billion in the fiscal first quarter of 2021 related to two brands outside the U.S. •Intangible amortization expense of $0.8 billion and $0.9 billion in the fiscal first quarter of 2022 and 2021, respectively •In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. •A loss of $0.4 billion related to the change in the fair value of securities in the fiscal first quarter of 2022 In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. The Company continues to evaluate the global demand for the COVID-19 vaccine and its related supply. (3) MedTech includes: •A restructuring related charge of $0.1 billion in both the fiscal first quarter of 2022 and 2021 •Intangible amortization expense of $0.3 billion in both the fiscal first quarter of 2022 and 2021 (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas | SALES BY GEOGRAPHIC AREA
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | Percent Change |  |  |  |  |  |
United States |  | $ | 11,414 |  |  | 11,111 |  |  | 2.7 | % |  |  |  |  |  |
Europe |  | 6,024 |  |  | 5,414 |  |  | 11.3 |  |  |  |  |  |  |
Western Hemisphere, excluding U.S. |  | 1,482 |  |  | 1,424 |  |  | 4.1 |  |  |  |  |  |  |
Asia-Pacific, Africa |  | 4,506 |  |  | 4,372 |  |  | 3.1 |  |  |  |  |  |  |
Total |  | $ | 23,426 |  |  | 22,321 |  |  | 5.0 | % |  |  |  |  |  |

X
- Definition Sales by segment of business. + References No definition available. + Details
Name: | jnj_SalesBySegmentOfBusinessTableTextBlock
Namespace Prefix: | jnj_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration